Antonio Villaverde Selected Research

Peptides (Polypeptides)

5/2022	Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors.
12/2021	Ion-dependent slow protein release from in vivo disintegrating micro-granules.
6/2021	Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers.
11/2020	Nanostructured antimicrobial peptides: The last push towards clinics.
2/2020	Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells.
11/2019	Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer.
1/2017	Engineering tumor cell targeting in nanoscale amyloidal materials.
10/2016	Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders.
4/2016	Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli.
1/2009	Modular protein engineering in emerging cancer therapies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antonio Villaverde Research Topics

Disease

42	Neoplasms (Cancer) 12/2022 - 01/2009
9	Colorectal Neoplasms (Colorectal Cancer) 06/2021 - 01/2012
5	Neoplasm Metastasis (Metastasis) 12/2022 - 01/2019
5	Lymphoma (Lymphomas) 06/2022 - 01/2020
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2018
5	Infections 11/2021 - 05/2003
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 06/2022 - 01/2020
3	Squamous Cell Carcinoma of Head and Neck 05/2022 - 02/2022
3	Fabry Disease (Fabry's Disease) 01/2021 - 04/2016
2	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2021 - 04/2007
2	Amyloidosis 02/2021 - 04/2007
1	Diphtheria 02/2022
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 02/2021
1	Parkinson Disease (Parkinson's Disease) 02/2021
1	Multiple System Atrophy 02/2021
1	Communicable Diseases (Infectious Diseases) 11/2020
1	Triple Negative Breast Neoplasms 02/2020
1	Residual Neoplasm 01/2020
1	Breast Neoplasms (Breast Cancer) 09/2019
1	Chronic Disease (Chronic Diseases) 09/2019
1	Virus Diseases (Viral Diseases) 01/2018
1	Hemorrhagic Septicemia (Haemorrhagic Septicemia) 01/2018
1	Necrosis 01/2018
1	Leukemia 01/2018
1	Bacterial Infections (Bacterial Infection) 01/2017
1	Central Nervous System Diseases (CNS Diseases) 03/2015
1	Sarcoma (Soft Tissue Sarcoma) 02/2015
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2014

Drug/Important Bio-Agent (IBA)

36	Proteins (Proteins, Gene)FDA Link 05/2022 - 04/2007
23	Pharmaceutical PreparationsIBA 12/2022 - 01/2009
11	Peptides (Polypeptides)IBA 05/2022 - 04/2002
8	LigandsIBA 02/2022 - 10/2016
6	NanoconjugatesIBA 01/2022 - 10/2016
4	Chemokine ReceptorsIBA 05/2022 - 01/2018
4	EnzymesIBA 01/2021 - 04/2002
4	Drug CarriersIBA 02/2020 - 10/2016
3	Diphtheria ToxinIBA 06/2022 - 10/2021
3	Antineoplastic Agents (Antineoplastics)IBA 10/2021 - 01/2018
3	CXCR4 Receptors (CXCR4 Receptor)IBA 01/2020 - 01/2012
3	Recombinant ProteinsIBA 01/2018 - 05/2003
2	Cytotoxins (Cytolysins)IBA 12/2022 - 05/2022
2	Bacterial ToxinsIBA 05/2022 - 01/2020
2	ExotoxinsIBA 02/2022 - 01/2020
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2022 - 11/2021
2	monomethyl auristatin EIBA 01/2022 - 01/2022
2	auristatinIBA 01/2021 - 01/2020
2	GalactosidasesIBA 10/2016 - 04/2016
1	nidogen (entactin)IBA 04/2022
1	Staphylococcal Protein A (Protein A)IBA 04/2022
1	Propidium (Propidium Iodide)IBA 02/2022
1	Caspase 3 (Caspase-3)IBA 02/2022
1	T22 peptideIBA 02/2022
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022
1	ProdrugsIBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 06/2021
1	Human Serum Albumin FDA LinkGeneric 06/2021
1	Floxuridine (FUdR)FDA LinkGeneric 01/2021
1	Drug CombinationsIBA 01/2021
1	Fluorescent Dyes (Fluorescent Probes)IBA 10/2020
1	nucleolin binding peptideIBA 02/2020
1	NucleolinIBA 02/2020
1	Cell Surface ReceptorsIBA 02/2020
1	Pseudomonas exotoxin PE24IBA 02/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020
1	plerixafor FDA Link 01/2020
1	Prednisone (Sone)FDA LinkGeneric 01/2020
1	Rituximab (Mabthera)FDA Link 01/2020
1	Vincristine (Oncovin)FDA LinkGeneric 01/2020
1	Immunotoxins (Immunotoxin)IBA 01/2020
1	OligonucleotidesIBA 03/2019
1	Dyneins (Dynein)IBA 01/2018
1	A-Form DNA (A-DNA)IBA 01/2018
1	RicinIBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 01/2018
1	Cell-Penetrating PeptidesIBA 01/2018
1	Arginine (L-Arginine)FDA Link 01/2018
1	Therapeutic UsesIBA 01/2018
1	Viral ProteinsIBA 01/2018
1	Green Fluorescent ProteinsIBA 01/2017
1	Antimicrobial Cationic PeptidesIBA 01/2017
1	PolyelectrolytesIBA 10/2016
1	ChitosanIBA 10/2016
1	Carrier Proteins (Binding Protein)IBA 10/2016
1	GlycosphingolipidsIBA 04/2016
1	Biological ProductsIBA 06/2015
1	Angiopoietin-2IBA 02/2015
1	IntegrinsIBA 02/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015
1	CXC ChemokinesIBA 02/2015
1	Valine (L-Valine)FDA Link 02/2015
1	Codon (Codons)IBA 02/2015
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 10/2013

Therapy/Procedure

21	Therapeutics 06/2022 - 01/2009
4	Drug Therapy (Chemotherapy) 10/2021 - 01/2020
1	Aftercare (After-Treatment) 02/2022
1	Intravenous Administration 01/2020
1	Intravenous Injections 01/2020